New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Alzamend Neuro, Inc. (ALZN) vs Pulmatrix, Inc. (PULM)

Alzamend Neuro, Inc. and Pulmatrix, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and Pulmatrix, Inc. are of similar size ($4.9M and $4.9M). Across the 9 metrics below, Alzamend Neuro, Inc. leads on 5 and Pulmatrix, Inc. on 4.

Valuation

Metric ALZN PULM Biotechnology median
P/E n/m n/m 8.26
P/S n/m 0.66 9.20
P/B 0.79 14.24 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.30 n/m 0.67
EV/Sales n/m 0.94 9.05
Earnings yield (225.49%) (85.15%) (34.24%)
Free cash flow yield (156.37%) (79.15%) (24.77%)

Profitability

Metric ALZN PULM Biotechnology median
Gross margin 0.00% 100.00% 70.18%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) (172.27%) (51.58%)
Return on assets (122.36%) (119.43%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN PULM Biotechnology median
Revenue growth (TTM) — 6.96% 7.20%
EPS growth (last fiscal year) 76.77% 46.18% 29.04%
Revenue growth, 5-year CAGR — (0.26%) 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN PULM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 2.32 4.83
Net debt to EBITDA 0.08 0.79 1.01

Dividend

Metric ALZN PULM Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric ALZN PULM Biotechnology median
Market cap 4.92m 4.89m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack